# Question 59

**Type:** Out of scope

**Question:** Are there studies that were not processed using polyA enrichment in order to explore lncRNA-related questions?

**Answer:**

I'll help you find studies that used methods other than polyA enrichment, which would be better suited for lncRNA research. Let me search for studies and examine their RNA sequencing methodologies.



Calling `list_studies` with args:
```json
{
  "search": "RNA",
  "limit": 50
}
```



Result from `list_studies`:
```json

```


Let me search more broadly and then check the database for information about RNA sequencing methods:



Calling `clickhouse_list_tables` with args:
```json
{}
```



Result from `clickhouse_list_tables`:
```json
{"tables":[{"name":"allele_specific_copy_number","total_rows":0,"comment":"Allele-specific CNA data for mutations. References mutation_event, genetic_profile, and sample."},{"name":"alteration_driver_annotation","total_rows":37356,"comment":"Annotations for genetic alterations classified as potential drivers. References genetic_profile and sample."},{"name":"cancer_study","total_rows":511,"comment":"Contains metadata for each cancer study in the portal. References type_of_cancer and reference_genome."},{"name":"cancer_study_tags","total_rows":0,"comment":"Tags associated with a cancer study. References cancer_study."},{"name":"clinical_attribute_meta","total_rows":18230,"comment":"Metadata describing clinical attributes. References cancer_study."},{"name":"clinical_data_derived","primary_key":"cancer_study_identifier, type, attribute_name, sample_unique_id","total_rows":11763690,"comment":"Unified clinical data table combining both patient-level and sample-level clinical attributes in a normalized key-value format. Uses FULL OUTER JOIN to ensure all defined clinical attributes appear for each patient/sample, even when no value is recorded (populated with empty string). Enables efficient querying of clinical data across different attribute types and levels."},{"name":"clinical_event","total_rows":2643379,"comment":"Time-bound clinical events for patients. References patient."},{"name":"clinical_event_data","total_rows":14395558,"comment":"Key-value attributes for clinical events. References clinical_event."},{"name":"clinical_event_derived","primary_key":"cancer_study_identifier, event_type, patient_unique_id","total_rows":14422476,"comment":"Denormalized clinical timeline events table combining temporal clinical events with their associated key-value attributes. Each row represents a specific attribute of a clinical event (e.g., treatment, surgery, specimen collection) with start/stop dates. Flattens the normalized clinical_event and clinical_event_data relationship into a queryable format for timeline analysis."},{"name":"clinical_patient","total_rows":4157292,"comment":"Patient-level clinical attribute values. References patient."},{"name":"clinical_sample","total_rows":5323875,"comment":"Sample-level clinical attribute values. References sample."},{"name":"cna_event","total_rows":77018,"comment":"Copy number alteration event definition. References gene."},{"name":"copy_number_seg","total_rows":28149618,"comment":"Raw segmented copy number data. References cancer_study and sample."},{"name":"copy_number_seg_file","total_rows":292,"comment":"File metadata for segmented copy number input. References cancer_study."},{"name":"gene","total_rows":46303,"comment":"Gene metadata (Entrez ID, HUGO symbol). References genetic_entity."},{"name":"gene_alias","total_rows":75207,"comment":"Alternative symbols/aliases for genes. References gene."},{"name":"gene_panel","total_rows":58,"comment":"Defines a targeted gene panel used in sequencing."},{"name":"gene_panel_list","total_rows":21477,"comment":"Join table linking gene panels to genes. References gene_panel and gene."},{"name":"generic_assay_data_derived","primary_key":"profile_type, entity_stable_id, patient_unique_id, sample_unique_id","total_rows":394482832,"comment":"Denormalized generic assay data table that unpivots wide-format genetic_alteration values for generic assay profiles into a long-format structure. Handles diverse assay types like treatment response, phosphosite quantification, and other non-genomic measurements. Each row represents one entity-sample combination with its measured value. Supports both sample-level and patient-level data based on profile configuration."},{"name":"generic_entity_properties","total_rows":2490012,"comment":"Properties for generic entities. References genetic_entity."},{"name":"geneset","total_rows":34837,"comment":"Collection of genes grouped into functional sets. References genetic_entity."},{"name":"geneset_gene","total_rows":8050756,"comment":"Join table linking genesets to genes. References geneset and gene."},{"name":"geneset_hierarchy_leaf","total_rows":0,"comment":"Mapping of hierarchy nodes to specific gene sets. References geneset_hierarchy_node and geneset."},{"name":"geneset_hierarchy_node","total_rows":0,"comment":"Hierarchy node for organizing gene sets. May reference parent node within same table."},{"name":"genetic_alteration","primary_key":"genetic_profile_id, genetic_entity_id","total_rows":33488996,"comment":"Stores genetic alteration values (for many genetic alteration types. e.g. MRNA_EXPRESSION, PROTEIN_LEVEL, GENERIC_ASSAY,...). References genetic_profile and genetic_entity."},{"name":"genetic_alteration_derived","primary_key":"cancer_study_identifier, hugo_gene_symbol, profile_type, sample_unique_id","total_rows":10133300301,"comment":"Denormalized genetic alteration data table that unpivots the wide-format genetic_alteration values into a long-format structure. Each row represents one gene-sample-profile combination with its alteration value. Excludes mutation data (handled separately) and generic assays, focusing on continuous/discrete data like expression, methylation, and copy number. Filters out \"NA\" values to reduce storage and improve query performance."},{"name":"genetic_entity","total_rows":2508068,"comment":"Abstract entity representing a gene, gene set, or other genomic element."},{"name":"genetic_profile","total_rows":2405,"comment":"Defines a molecular profile (e.g. mutations, CNA, mRNA expression). References cancer_study."},{"name":"genetic_profile_link","total_rows":2,"comment":"Links between genetic profiles. References genetic_profile (source and target)."},{"name":"genetic_profile_samples","total_rows":1896,"comment":"Stores ordered sample lists for a genetic profile (for many genetic alteration types. e.g. MRNA_EXPRESSION, PROTEIN_LEVEL, GENERIC_ASSAY,...). References genetic_profile."},{"name":"genomic_event_derived","primary_key":"genetic_profile_stable_id, cancer_study_identifier, variant_type, entrez_gene_id, hugo_gene_symbol, sample_unique_id","total_rows":48903328,"comment":"Unified genomic events table combining mutations, copy number alterations (CNA), and structural variants into a single denormalized view. Each row represents a gene-level genomic event observed in a sample. Structural variants are split into separate rows for site1 and site2 genes (excluding duplicates). Includes off-panel detection to identify events in genes not covered by the associated gene panel."},{"name":"gistic","total_rows":3547,"comment":"GISTIC-identified copy number alteration regions. References cancer_study."},{"name":"gistic_to_gene","total_rows":204806,"comment":"Mapping of GISTIC regions to genes. References gistic and gene."},{"name":"info","total_rows":1},{"name":"mut_sig","total_rows":2850,"comment":"MutSig significance analysis results. References cancer_study and gene."},{"name":"mutation","primary_key":"genetic_profile_id, entrez_gene_id","total_rows":17774534,"comment":"Mutation observations in specific samples and profiles. References mutation_event, gene, genetic_profile, and sample."},{"name":"mutation_count_by_keyword","total_rows":12451447,"comment":"Stores keyword-based aggregated mutation counts. References genetic_profile and gene."},{"name":"mutation_event","total_rows":8850403,"comment":"Defines unique mutation events (by position, gene, allele change). References gene."},{"name":"patient","total_rows":320721,"comment":"Stores patient-level identifiers of patients enrolled in a cancer study. References cancer_study."},{"name":"reference_genome","total_rows":3,"comment":"Reference genome definitions (e.g. hg19, GRCh38)."},{"name":"reference_genome_gene","total_rows":84612,"comment":"Mapping of reference genome builds to genes. References reference_genome and gene."},{"name":"resource_definition","total_rows":43,"comment":"Definitions of external resources (study, patient, sample level). References cancer_study."},{"name":"resource_patient","total_rows":10471,"comment":"Links external resources to patients. References patient."},{"name":"resource_sample","total_rows":3711,"comment":"Links external resources to samples. References sample."},{"name":"resource_study","total_rows":0,"comment":"Links external resources to cancer studies. References cancer_study."},{"name":"sample","total_rows":336873,"comment":"Biological samples collected from patients. References patient."},{"name":"sample_cna_event","primary_key":"genetic_profile_id, cna_event_id, sample_id","total_rows":30879655,"comment":"Observed CNA events per sample and profile. References cna_event, sample, and genetic_profile."},{"name":"sample_derived","primary_key":"cancer_study_identifier, sample_unique_id","total_rows":336873,"comment":"Denormalized sample table with globally unique identifiers and enriched metadata. Combines sample, patient, and cancer_study data with computed flags for sequencing status and copy number segment availability. Optimized for summary and detailed projections with base64-encoded identifiers for URL-safe usage."},{"name":"sample_list","total_rows":2727,"comment":"Named collections of samples within a study. References cancer_study."},{"name":"sample_list_list","total_rows":1452133,"comment":"Join table linking sample lists to samples. References sample and sample_list."},{"name":"sample_profile","total_rows":1090903,"comment":"Links samples to genetic profiles, optionally via a gene panel. References sample, genetic_profile, and gene_panel."},{"name":"sample_to_gene_panel_derived","primary_key":"gene_panel_id, alteration_type, genetic_profile_id, sample_unique_id","total_rows":1090903,"comment":"Denormalized mapping table linking samples to their associated gene panels for each genetic alteration type. Derived from sample_profile, genetic_profile, gene_panel, sample, and cancer_study tables. Defaults to WES (Whole Exome Sequencing) when no specific gene panel is assigned."},{"name":"structural_variant","total_rows":148760,"comment":"Structural variant data (fusions, translocations). References genetic_profile, sample, and gene (site1/site2)."},{"name":"type_of_cancer","total_rows":898,"comment":"Lookup table for cancer types."}]}
```


Now let me query for studies and check if there's information about RNA sequencing methods in the clinical attributes or study metadata:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT \n    attr_id,\n    description,\n    COUNT(DISTINCT cancer_study_id) as num_studies\nFROM clinical_attribute_meta\nWHERE lower(attr_id) LIKE '%rna%' \n   OR lower(attr_id) LIKE '%seq%'\n   OR lower(description) LIKE '%rna%'\n   OR lower(description) LIKE '%polya%'\n   OR lower(description) LIKE '%ribosomal%'\n   OR lower(description) LIKE '%rrna%'\n   OR lower(description) LIKE '%enrichment%'\nGROUP BY attr_id, description\nORDER BY num_studies DESC\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[{"attr_id":"ICD_10","description":"10th revision of the International Statistical Classification of Diseases and Related Health Problems.","num_studies":70},{"attr_id":"ICD_O_3_SITE","description":"The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The description of an anatomical region or of a body part._Named locations of, or within, the body._A system of numbered categories for representation of data.","num_studies":68},{"attr_id":"ICD_O_3_HISTOLOGY","description":"The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._A system of numbered categories for representation of data.","num_studies":66},{"attr_id":"PRIMARY_DIAGNOSIS","description":"Text term used to describe the patient's histologic diagnosis, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).","num_studies":46},{"attr_id":"ICD_10","description":"Alphanumeric value used to describe the disease code from the tenth version of the International Classification of Disease (ICD-10).","num_studies":32},{"attr_id":"AGE_AT_SEQ_REPORTED_YEARS","description":"Age (in years) at which sequencing was reported","num_studies":29},{"attr_id":"WINTER_HYPOXIA_SCORE","description":"mRNA based Winter Hypoxia Score","num_studies":19},{"attr_id":"RAGNUM_HYPOXIA_SCORE","description":"mRNA based Ragnum Hypoxia Score","num_studies":19},{"attr_id":"BUFFA_HYPOXIA_SCORE","description":"mRNA based Buffa Hypoxia Score","num_studies":19},{"attr_id":"SEQUENCED","description":"Sequenced.","num_studies":7},{"attr_id":"SEQUENCING_TYPE","description":"Sequencing Type","num_studies":7},{"attr_id":"AGE_AT_SEQ_REPORT","description":"Age (in days) at which sequencing was reported","num_studies":5},{"attr_id":"FIGO_GRADE","description":"The extent of a cervical or endometrial cancer within the body, especially whether the disease has spread from the original site to other parts of the body, as described by the International Federation of Gynecology and Obstetrics (FIGO) stages.","num_studies":4},{"attr_id":"RNASEQ_DATA","description":"RNA-SEQ data.","num_studies":4},{"attr_id":"MIRNA_CLUSTER","description":"MICRNA cluster","num_studies":4},{"attr_id":"SEQUENCING_PLATFORM","description":"Sequencing Platform","num_studies":3},{"attr_id":"WHOLE_EXOME_SEQUENCING","description":"Whole Exome Sequencing","num_studies":3},{"attr_id":"CYTOLYTIC_SCORE","description":"RNA-Seq Cytolytic Score","num_studies":3},{"attr_id":"MRNA_EXPRESSION_CLUSTER","description":"MRNA expression cluster.","num_studies":3},{"attr_id":"MRNA_DATA","description":"MRNA data.","num_studies":3},{"attr_id":"IPI","description":"International Prognostic Index (IPI)","num_studies":3},{"attr_id":"SITE_SEQUENCED","description":"Site Sequenced","num_studies":2},{"attr_id":"ICD_O_3_SITE","description":" The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The description of an anatomical region or of a body part._Named locations of, or within, the body._A system of numbered categories for representation of data.","num_studies":2},{"attr_id":"AGE_AT_SEQUENCING","description":"Age at Sequencing","num_studies":2},{"attr_id":"RNA_SEQUENCED","description":"RNA Sequenced","num_studies":2},{"attr_id":"ICD_O_3_HISTOLOGY","description":" The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._A system of numbered categories for representation of data.","num_studies":2},{"attr_id":"TISSUE_SEQUENCED","description":"Tissue Sequnced","num_studies":2},{"attr_id":"ETS_FUSION_SEQ","description":"ETS fusion seq","num_studies":2},{"attr_id":"ALTERNATE_THERAPY_OTHER","description":"Other Alternative Therapy Given","num_studies":2},{"attr_id":"WHOLE_GENOME_SEQUENCING","description":"Whole Genome Sequencing","num_studies":2},{"attr_id":"PROTHROMBIN_TIME_NORM_RANGE_UPPER","description":"Laboratory procedure international normalization ratio result upper limit of normal value","num_studies":2},{"attr_id":"TIME_FROM_DX_TO_SEQ","description":"Time from Diagnosis to sequencing (days)","num_studies":2},{"attr_id":"TISSUE_SEQUENCED","description":"Tissue Sequenced","num_studies":2},{"attr_id":"INSS_STAGE","description":"Staging according to the International Neuroblastoma Staging System","num_studies":2},{"attr_id":"SEQUENCING_PLATFORM","description":"Sequencing platform","num_studies":2},{"attr_id":"PROTHROM_TIME_INR_NORM_RANGE_LOWER","description":"Laboratory procedure international normalization ratio result lower limit of normal value","num_studies":2},{"attr_id":"RNA_DATA","description":"RNA data","num_studies":1},{"attr_id":"IDH_SPECIFIC_RNA_EXPRESSION_CLUSTER","description":"IDH-specific RNA Expression Cluster","num_studies":1},{"attr_id":"AGE_AT_SEQ_REPORTED_YEARS","description":"Age at Sequencing (years)","num_studies":1},{"attr_id":"IMMUNE_SCORE","description":"An ssGSEA-based enrichment score calculated from the ESTIMATE immune signature. Represents general immune content in a given tumor.","num_studies":1},{"attr_id":"ICD_O_3_SITE","description":"\"The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The description of an anatomical region or of a body part._Named locations of, or within, the body._A system of numbered categories for representation of data.\"","num_studies":1},{"attr_id":"SEQCAP_EZ_EXOME_VERSION","description":"SEQCAP EZ EXOME VERSION","num_studies":1},{"attr_id":"RADIATION_THERAPY_DOSE_PARAAORTIC_NODES","description":"External beam radiation therapy administered paraaortic region lymph node dose","num_studies":1},{"attr_id":"HPV_PATHSEQ","description":"Tumor human papilloma virus status by PathSeq: Positive/Negative","num_studies":1},{"attr_id":"RNA_SEQUENCING","description":"Sample included in RNA-Sequencing","num_studies":1},{"attr_id":"RNASEQ_R1_SAMPLE_TYPE","description":"RNAseq R1 Sample Type","num_studies":1},{"attr_id":"CHEMO_EXP_SEQ_SPECIMEN","description":"Chemo Exposure of sequenced specimen","num_studies":1},{"attr_id":"SUBSEQUENT_RX","description":"Subsequent Rx","num_studies":1},{"attr_id":"ESTIMATE_TUMORPURITY","description":"Tumor purity inferred from mRNA using the ESTIMATE algorithm","num_studies":1},{"attr_id":"RNA_TEL_CONTENT","description":"RNA telomere content estimated using TelomereHunter","num_studies":1}]}
```


Let me search more specifically for information about library preparation methods:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT \n    attr_id,\n    description\nFROM clinical_attribute_meta\nWHERE lower(attr_id) LIKE '%library%' \n   OR lower(attr_id) LIKE '%prep%'\n   OR lower(attr_id) LIKE '%protocol%'\n   OR lower(description) LIKE '%library%'\n   OR lower(description) LIKE '%polya%'\n   OR lower(description) LIKE '%poly-a%'\n   OR lower(description) LIKE '%poly a%'\n   OR lower(description) LIKE '%ribosomal%'\n   OR lower(description) LIKE '%rrna%'\n   OR lower(description) LIKE '%depletion%'\n   OR lower(description) LIKE '%enrichment%'\n   OR lower(description) LIKE '%selection%'\nLIMIT 100\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[{"attr_id":"ALLELE_SELECTION","description":"KRAS allele selection"},{"attr_id":"AR_POLYA_SCORE","description":"AR Score (PolyA)"},{"attr_id":"IMMUNE_SCORE","description":"An ssGSEA-based enrichment score calculated from the ESTIMATE immune signature. Represents general immune content in a given tumor."},{"attr_id":"NEPC_POLYA_SCORE","description":"NEPC Score (PolyA)"},{"attr_id":"NORMAL_GENOME_LIBRARY","description":"Normal Genome Library"},{"attr_id":"POLYA_ARV7_SRPM","description":"polyA ARV7 SRPM spliced reads per million"},{"attr_id":"PROTOCOL","description":"Protocol."},{"attr_id":"PROTOCOL_AND_TREATMENT_ARM","description":"Protocol and Treatment Arm"},{"attr_id":"SELECTION_LABEL","description":"KRAS allele selection state"},{"attr_id":"STROMAL_SCORE","description":"An ssGSEA-based enrichment score calculated from the ESTIMATE stromal signature. Represents stromal content in a given tumor."},{"attr_id":"TUMOR_GENOME_LIBRARY","description":"Tumor Genome Library"}]}
```


Good! I found some relevant attributes. Now let me check which studies have information about library preparation or RNA-seq methods:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT\n    cs.cancer_study_identifier,\n    cs.name,\n    cs.description\nFROM cancer_study cs\nWHERE lower(cs.description) LIKE '%rrna%'\n   OR lower(cs.description) LIKE '%ribosomal%'\n   OR lower(cs.description) LIKE '%polya%'\n   OR lower(cs.description) LIKE '%poly-a%'\n   OR lower(cs.description) LIKE '%depletion%'\n   OR lower(cs.description) LIKE '%lncrna%'\n   OR lower(cs.description) LIKE '%long non-coding%'\n   OR lower(cs.description) LIKE '%total rna%'\nORDER BY cs.cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[]}
```


Let me check the genetic_profile table, which might contain information about RNA-seq methods:



Calling `clickhouse_list_table_columns` with args:
```json
{
  "table": "genetic_profile"
}
```



Result from `clickhouse_list_table_columns`:
```json
{"columns":[{"name":"genetic_profile_id","type":"Nullable(Int64)","comment":"Primary key. Unique identifier for the genetic profile."},{"name":"stable_id","type":"Nullable(String)","comment":"Stable external identifier of the genetic profile."},{"name":"cancer_study_id","type":"Nullable(Int64)","comment":"References cancer_study.cancer_study_id."},{"name":"genetic_alteration_type","type":"Nullable(String)","comment":"Type of genetic alteration (e.g. MUTATION_EXTENDED, COPY_NUMBER_ALTERATION, MRNA_EXPRESSION, PROTEIN_LEVEL, GENERIC_ASSAY, STRUCTURAL_VARIANT, METHYLATION)."},{"name":"generic_assay_type","type":"Nullable(String)","comment":"Type of assay used (TREATMENT_RESPONSE, PHOSPHOSITE_QUANTIFICATION, ...;only if genetic_alteration_type=GENERIC_ASSAY)."},{"name":"datatype","type":"Nullable(String)","comment":"Datatype of the profile (e.g. MAF, DISCRETE, CONTINUOUS, LOG2-VALUE, Z-SCORE, LIMIT-VALUE, CATEGORICAL, SV,...). Togather with genetic_alteration_type defines a unique datatype."},{"name":"name","type":"Nullable(String)","comment":"Human-readable name of the genetic profile."},{"name":"description","type":"Nullable(String)","comment":"Detailed description of the genetic profile."},{"name":"show_profile_in_analysis_tab","type":"Nullable(Int32)","comment":"Flag to indicate if this profile should be shown in analysis tab."},{"name":"pivot_threshold","type":"Nullable(Float64)","comment":"Threshold value used for pivoting in visualization (optional)."},{"name":"sort_order","type":"Nullable(String)","comment":"Sort order of values in the profile (ASC or DESC; optional)."},{"name":"patient_level","type":"Nullable(Int32)","comment":"Indicates if profile is at patient level (1) or sample level (0)."}]}
```




Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT\n    cs.cancer_study_identifier,\n    cs.name,\n    gp.name as profile_name,\n    gp.description as profile_description\nFROM genetic_profile gp\nJOIN cancer_study cs ON gp.cancer_study_id = cs.cancer_study_id\nWHERE gp.genetic_alteration_type = 'MRNA_EXPRESSION'\n  AND (lower(gp.description) LIKE '%rrna%'\n   OR lower(gp.description) LIKE '%ribosomal%'\n   OR lower(gp.description) LIKE '%polya%'\n   OR lower(gp.description) LIKE '%poly-a%'\n   OR lower(gp.description) LIKE '%depletion%'\n   OR lower(gp.description) LIKE '%total rna%'\n   OR lower(gp.description) LIKE '%library%')\nORDER BY cs.cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[{"cancer_study_identifier":"prad_su2c_2019","cs.name":"Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)","profile_name":"mRNA expression (FPKM polyA)","profile_description":"mRNA expression from polyA (RNA Seq FPKM)"},{"cancer_study_identifier":"prad_su2c_2019","cs.name":"Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)","profile_name":"mRNA expression z-scores relative to diploid samples (FPKM polyA)","profile_description":"mRNA expression from polyA Z-scores (RNA Seq FPKM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"prad_su2c_2019","cs.name":"Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)","profile_name":"mRNA expression z-scores relative to all samples (log FPKM polyA)","profile_description":"Log-transformed mRNA z-scores compared to expression distribution of all samples (RNA Seq FPKM polyA)."}]}
```


Great! Now let me search for studies that explicitly mention rRNA depletion or total RNA methods:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT\n    cs.cancer_study_identifier,\n    cs.name,\n    gp.name as profile_name,\n    gp.description as profile_description,\n    gp.genetic_alteration_type\nFROM genetic_profile gp\nJOIN cancer_study cs ON gp.cancer_study_id = cs.cancer_study_id\nWHERE (lower(gp.name) LIKE '%rrna%'\n   OR lower(gp.name) LIKE '%ribosomal%'\n   OR lower(gp.name) LIKE '%depletion%'\n   OR lower(gp.name) LIKE '%total rna%'\n   OR lower(gp.name) LIKE '%total-rna%'\n   OR lower(gp.description) LIKE '%rrna%'\n   OR lower(gp.description) LIKE '%ribosomal%'\n   OR lower(gp.description) LIKE '%depletion%'\n   OR lower(gp.description) LIKE '%total rna%'\n   OR lower(gp.description) LIKE '%total-rna%')\nORDER BY cs.cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[]}
```


Let me check all RNA expression profiles to see what methods are mentioned:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT\n    cs.cancer_study_identifier,\n    cs.name,\n    gp.name as profile_name,\n    gp.description as profile_description\nFROM genetic_profile gp\nJOIN cancer_study cs ON gp.cancer_study_id = cs.cancer_study_id\nWHERE gp.genetic_alteration_type = 'MRNA_EXPRESSION'\n  AND gp.description != ''\nORDER BY cs.cancer_study_identifier\nLIMIT 100\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[{"cancer_study_identifier":"acc_tcga","cs.name":"Adrenocortical Carcinoma (TCGA, Firehose Legacy)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA expression z-scores compared to the expression distribution of all samples (RNA Seq V2 RSEM)."},{"cancer_study_identifier":"acc_tcga","cs.name":"Adrenocortical Carcinoma (TCGA, Firehose Legacy)","profile_name":"mRNA expression (RNA Seq V2 RSEM)","profile_description":"mRNA gene expression (RNA Seq V2 RSEM)"},{"cancer_study_identifier":"acc_tcga","cs.name":"Adrenocortical Carcinoma (TCGA, Firehose Legacy)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)","profile_description":"mRNA expression z-scores (RNA Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"acc_tcga_gdc","cs.name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","profile_name":"mRNA Expression","profile_description":"Expression levels"},{"cancer_study_identifier":"acc_tcga_gdc","cs.name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","profile_name":"mRNA Expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"acc_tcga_gdc","cs.name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","profile_name":"mRNA Expression FPKM z-scores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"acc_tcga_gdc","cs.name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","profile_name":"mRNA Expression z-scores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"acc_tcga_gdc","cs.name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","profile_name":"mRNA Expression TPM z-scores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"acc_tcga_gdc","cs.name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","profile_name":"mRNA Expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"acc_tcga_pan_can_atlas_2018","cs.name":"Adrenocortical Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2)","profile_description":"mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2)"},{"cancer_study_identifier":"acc_tcga_pan_can_atlas_2018","cs.name":"Adrenocortical Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)","profile_description":"mRNA expression z-scores (RNA Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"acc_tcga_pan_can_atlas_2018","cs.name":"Adrenocortical Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA expression z-scores compared to the expression distribution of all samples (RNA Seq V2 RSEM)."},{"cancer_study_identifier":"alal_target_gdc","cs.name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","profile_name":"mRNA Expression TPM z-scores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"alal_target_gdc","cs.name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","profile_name":"mRNA Expression z-scores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"alal_target_gdc","cs.name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","profile_name":"mRNA Expression","profile_description":"Expression levels"},{"cancer_study_identifier":"alal_target_gdc","cs.name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","profile_name":"mRNA Expression FPKM z-scores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"alal_target_gdc","cs.name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","profile_name":"mRNA Expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"alal_target_gdc","cs.name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","profile_name":"mRNA Expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"mRNA expression (microarray)","profile_description":"mRNA expression levels (Affymetrix microarray)"},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"mRNA expression z-scores relative to diploid samples (microarray)","profile_description":"mRNA z-Scores (Agilent microarray) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"mRNA expression z-scores relative to all samples (log microarray)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples  (Agilent microarray)."},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"mRNA expression (RNA Seq RPKM)","profile_description":"Expression levels for 26136 genes in 203 all cases (RNA-Seq RPKM)."},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq RPKM)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples (RNA-Seq RPKM)."},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"microRNA expression","profile_description":"Expression levels for microRNAs."},{"cancer_study_identifier":"all_phase2_target_2018_pub","cs.name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq RPKM)","profile_description":"mRNA z-Scores (RNA-Seq RPKM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"aml_ohsu_2018","cs.name":"Acute Myeloid Leukemia (OHSU, Nature 2018)","profile_name":"mRNA expression (RNA Seq RPKM)","profile_description":"Expression levels for genes in 451 AML cases (RNA Seq RPKM)."},{"cancer_study_identifier":"aml_ohsu_2018","cs.name":"Acute Myeloid Leukemia (OHSU, Nature 2018)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq CPM)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples (RNA Seq CPM)."},{"cancer_study_identifier":"aml_ohsu_2018","cs.name":"Acute Myeloid Leukemia (OHSU, Nature 2018)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq RPKM)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples (RNA Seq RPKM)."},{"cancer_study_identifier":"aml_ohsu_2018","cs.name":"Acute Myeloid Leukemia (OHSU, Nature 2018)","profile_name":"mRNA expression (RNA Seq CPM)","profile_description":"Expression levels for genes in 451 AML cases (RNA Seq CPM)."},{"cancer_study_identifier":"aml_ohsu_2022","cs.name":"Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)","profile_name":"mRNA expression (log2 RNA Seq RPKM)","profile_description":"mRNA expression derived from log2-normalized RPKM values"},{"cancer_study_identifier":"aml_ohsu_2022","cs.name":"Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq RPKM)","profile_description":"mRNA zscores derived from log2-normalized RPKM values"},{"cancer_study_identifier":"aml_target_2018_pub","cs.name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","profile_name":"microRNA expression","profile_description":"Expression levels for microRNAs."},{"cancer_study_identifier":"aml_target_2018_pub","cs.name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","profile_name":"mRNA expression (microarray)","profile_description":"mRNA expression levels (Affymetrix microarray)"},{"cancer_study_identifier":"aml_target_2018_pub","cs.name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","profile_name":"mRNA expression z-scores relative to all samples (log microarray)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples  (Agilent microarray)."},{"cancer_study_identifier":"aml_target_2018_pub","cs.name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","profile_name":"mRNA expression (RNA Seq RPKM)","profile_description":"Expression levels for genes in TARGET-AML Discovery cases (RNA-Seq RPKM)."},{"cancer_study_identifier":"aml_target_2018_pub","cs.name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq RPKM)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples (RNA Seq RPKM)."},{"cancer_study_identifier":"aml_target_gdc","cs.name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","profile_name":"mRNA Expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"aml_target_gdc","cs.name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","profile_name":"mRNA Expression","profile_description":"Expression levels"},{"cancer_study_identifier":"aml_target_gdc","cs.name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","profile_name":"mRNA Expression FPKM z-scores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"aml_target_gdc","cs.name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","profile_name":"mRNA Expression TPM z-scores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"aml_target_gdc","cs.name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","profile_name":"mRNA Expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"aml_target_gdc","cs.name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","profile_name":"mRNA Expression z-scores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"aml_tcga_gdc","cs.name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","profile_name":"mRNA Expression FPKM z-scores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"aml_tcga_gdc","cs.name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","profile_name":"mRNA Expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"aml_tcga_gdc","cs.name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","profile_name":"mRNA Expression","profile_description":"Expression levels"},{"cancer_study_identifier":"aml_tcga_gdc","cs.name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","profile_name":"mRNA Expression TPM z-scores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"aml_tcga_gdc","cs.name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","profile_name":"mRNA Expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"aml_tcga_gdc","cs.name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","profile_name":"mRNA Expression z-scores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"angs_painter_2025","cs.name":"The Angiosarcoma Project - Count Me In (Provisional, April 2025)","profile_name":"mRNA expression Z-Scores (log TPM)","profile_description":"Expression levels"},{"cancer_study_identifier":"angs_painter_2025","cs.name":"The Angiosarcoma Project - Count Me In (Provisional, April 2025)","profile_name":"mRNA expression (TPM)","profile_description":"Expression levels (TPM)"},{"cancer_study_identifier":"angs_painter_2025","cs.name":"The Angiosarcoma Project - Count Me In (Provisional, April 2025)","profile_name":"mRNA expression (Raw Counts)","profile_description":"mRNA Expression levels (raw read counts)"},{"cancer_study_identifier":"asclc_msk_2024","cs.name":"Atypical Small Cell Lung Cancer (MSK, Cancer Discov 2024)","profile_name":"mRNA expression normalized counts (TPM)","profile_description":"mRNA Expression (TPM)"},{"cancer_study_identifier":"asclc_msk_2024","cs.name":"Atypical Small Cell Lung Cancer (MSK, Cancer Discov 2024)","profile_name":"mRNA expression z-scores (TPM)","profile_description":"Expression levels z-scores (TPM)"},{"cancer_study_identifier":"blca_bcan_hcrn_2022","cs.name":"Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)","profile_name":"UC_GENOME_RNAseq_zscore","profile_description":"mRNA expression UQ_Log2_zscore."},{"cancer_study_identifier":"blca_msk_tcga_2020","cs.name":"Bladder Cancer (MSK/TCGA, 2020)","profile_name":"mRNA expression (RNA Seq V2 RSEM)","profile_description":"mRNA gene expression (RNA Seq V2 RSEM)"},{"cancer_study_identifier":"blca_msk_tcga_2020","cs.name":"Bladder Cancer (MSK/TCGA, 2020)","profile_name":"mRNA expression z-scores (RNA Seq V2 RSEM)","profile_description":"mRNA z-Scores (RNA Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"blca_msk_tcga_2020","cs.name":"Bladder Cancer (MSK/TCGA, 2020)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA expression z-scores compared to the expression distribution of all samples (RNA Seq V2 RSEM)."},{"cancer_study_identifier":"blca_mskcc_solit_2012","cs.name":"Bladder Cancer (MSK, J Clin Onco 2013)","profile_name":"mRNA expression z-scores relative to all samples (log microarray)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples  (Agilent microarray)."},{"cancer_study_identifier":"blca_mskcc_solit_2012","cs.name":"Bladder Cancer (MSK, J Clin Onco 2013)","profile_name":"mRNA expression z-scores relative to diploid samples (Illumina)","profile_description":"mRNA expression z-scores on 60 samples (Illumina microarrays) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"blca_mskcc_solit_2012","cs.name":"Bladder Cancer (MSK, J Clin Onco 2013)","profile_name":"mRNA expression","profile_description":"mRNA expression values on 60 samples (Illumina microarrays)"},{"cancer_study_identifier":"blca_pdx_msk_2025","cs.name":"Urothelial Cancer Patient Derived Organoids (MSK, 2025)","profile_name":"Pseudo bulk mRNA expression (log CPM)","profile_description":"The bulk RNA-seq counts were calculated from scRNA-seq, by averaging the raw expression counts per sample across the cells. The averaged raw counts are CPM normalized with log(1+x) transformation."},{"cancer_study_identifier":"blca_pdx_msk_2025","cs.name":"Urothelial Cancer Patient Derived Organoids (MSK, 2025)","profile_name":"Pseudo bulk mRNA expression z-scores","profile_description":"The bulk RNA-seq counts were calculated from scRNA-seq, by averaging the expression values per sample across the cells (log pseudo-bulk zscores)"},{"cancer_study_identifier":"blca_tcga","cs.name":"Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA expression z-scores compared to the expression distribution of all samples (RNA Seq V2 RSEM)."},{"cancer_study_identifier":"blca_tcga","cs.name":"Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)","profile_description":"mRNA expression z-scores (RNA Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"blca_tcga","cs.name":"Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)","profile_name":"mRNA expression (RNA Seq V2 RSEM)","profile_description":"mRNA gene expression (RNA Seq V2 RSEM)"},{"cancer_study_identifier":"blca_tcga_gdc","cs.name":"Bladder Urothelial Carcinoma (TCGA, GDC)","profile_name":"mRNA expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"blca_tcga_gdc","cs.name":"Bladder Urothelial Carcinoma (TCGA, GDC)","profile_name":"mRNA expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"blca_tcga_gdc","cs.name":"Bladder Urothelial Carcinoma (TCGA, GDC)","profile_name":"mRNA expression fpkm Zscores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"blca_tcga_gdc","cs.name":"Bladder Urothelial Carcinoma (TCGA, GDC)","profile_name":"mRNA expression","profile_description":"Expression levels"},{"cancer_study_identifier":"blca_tcga_gdc","cs.name":"Bladder Urothelial Carcinoma (TCGA, GDC)","profile_name":"mRNA expression Zscores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"blca_tcga_gdc","cs.name":"Bladder Urothelial Carcinoma (TCGA, GDC)","profile_name":"mRNA expression tpm Zscores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"blca_tcga_pan_can_atlas_2018","cs.name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA expression z-scores compared to the expression distribution of all samples (RNA Seq V2 RSEM)."},{"cancer_study_identifier":"blca_tcga_pan_can_atlas_2018","cs.name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA expression z-scores relative to normal samples (log RNA Seq V2 RSEM)","profile_description":"Expression z-scores of tumor samples compared to the expression distribution of all log-transformed mRNA expression of adjacent normal samples in the cohort."},{"cancer_study_identifier":"blca_tcga_pan_can_atlas_2018","cs.name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)","profile_description":"mRNA expression z-scores (RNA Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"blca_tcga_pan_can_atlas_2018","cs.name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","profile_name":"mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2)","profile_description":"mRNA Expression, RSEM (Batch normalized from Illumina HiSeq_RNASeqV2)"},{"cancer_study_identifier":"blca_tcga_pub","cs.name":"Bladder Urothelial Carcinoma (TCGA, Nature 2014)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)","profile_description":"mRNA z-Scores (RNA Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"blca_tcga_pub","cs.name":"Bladder Urothelial Carcinoma (TCGA, Nature 2014)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA z-Scores compared to the expression distribution of all samples (RNA Seq V2 RSEM)."},{"cancer_study_identifier":"blca_tcga_pub","cs.name":"Bladder Urothelial Carcinoma (TCGA, Nature 2014)","profile_name":"mRNA expression (RNA Seq V2 RSEM)","profile_description":"mRNA gene expression (RNA Seq V2 RSEM)"},{"cancer_study_identifier":"blca_tcga_pub_2017","cs.name":"Bladder Cancer (TCGA, Cell 2017)","profile_name":"mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)","profile_description":"mRNA z-Scores (RNA-Seq V2 RSEM) compared to the expression distribution of each gene tumors that are diploid for this gene."},{"cancer_study_identifier":"blca_tcga_pub_2017","cs.name":"Bladder Cancer (TCGA, Cell 2017)","profile_name":"mRNA expression (RNA Seq V2 RSEM)","profile_description":"mRNA gene expression (RNA Seq V2 RSEM)"},{"cancer_study_identifier":"blca_tcga_pub_2017","cs.name":"Bladder Cancer (TCGA, Cell 2017)","profile_name":"mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM)","profile_description":"Log-transformed mRNA z-scores compared to the expression distribution of all samples (RNA-Seq V2 RSEM)."},{"cancer_study_identifier":"bll_target_gdc","cs.name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","profile_name":"mRNA Expression FPKM z-scores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"bll_target_gdc","cs.name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","profile_name":"mRNA Expression","profile_description":"Expression levels"},{"cancer_study_identifier":"bll_target_gdc","cs.name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","profile_name":"mRNA Expression z-scores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"bll_target_gdc","cs.name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","profile_name":"mRNA Expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"bll_target_gdc","cs.name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","profile_name":"mRNA Expression TPM z-scores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"bll_target_gdc","cs.name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","profile_name":"mRNA Expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"brain_cptac_2020","cs.name":"Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)","profile_name":"RNA expression z-scores","profile_description":"Expression levels from RNA-Seq, Z scores of log2(FPKM + 1) values"},{"cancer_study_identifier":"brain_cptac_2020","cs.name":"Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)","profile_name":"RNA expression","profile_description":"Log2 of FPKM + 1 expresstion values. STAR v2.6.1d aligned + RSEM v1.3.1 quantification."},{"cancer_study_identifier":"brain_cptac_gdc","cs.name":"CNS/Brain Cancer (CPTAC GDC, 2025)","profile_name":"mRNA Expression TPM z-scores","profile_description":"mRNA expression from capture (RNA Seq TPM) zscores"},{"cancer_study_identifier":"brain_cptac_gdc","cs.name":"CNS/Brain Cancer (CPTAC GDC, 2025)","profile_name":"mRNA Expression z-scores","profile_description":"mRNA expression from capture read count zscores"},{"cancer_study_identifier":"brain_cptac_gdc","cs.name":"CNS/Brain Cancer (CPTAC GDC, 2025)","profile_name":"mRNA Expression (FPKM)","profile_description":"mRNA expression from capture (RNA Seq FPKM)"},{"cancer_study_identifier":"brain_cptac_gdc","cs.name":"CNS/Brain Cancer (CPTAC GDC, 2025)","profile_name":"mRNA Expression (TPM)","profile_description":"mRNA expression from capture (RNA Seq TPM)"},{"cancer_study_identifier":"brain_cptac_gdc","cs.name":"CNS/Brain Cancer (CPTAC GDC, 2025)","profile_name":"mRNA Expression","profile_description":"Expression levels"},{"cancer_study_identifier":"brain_cptac_gdc","cs.name":"CNS/Brain Cancer (CPTAC GDC, 2025)","profile_name":"mRNA Expression FPKM z-scores","profile_description":"mRNA expression from capture (RNA Seq FPKM) zscores"},{"cancer_study_identifier":"brca_aurora_2023","cs.name":"Metastatic Breast Cancer (AURORA US Network, Nat Cancer 2023)","profile_name":"mRNA Expression z-Scores (RNA Seq RSEM)","profile_description":"mRNA z-Scores log2 transformed (RNA Seq RSEM)"},{"cancer_study_identifier":"brca_cptac_2020","cs.name":"Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)","profile_name":"mRNA expression (FPKM, log2 transformed)","profile_description":"Gene expression by mRNA abundance in FPKM values (values of 0 were considered as missing and replaced by NA before applying log2 transformation)"},{"cancer_study_identifier":"brca_cptac_2020","cs.name":"Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)","profile_name":"Z-scores of mRNA expression (FPKM, log2 transformed)","profile_description":"Z-scores of mRNA abundance in FPKM values (log2 transformed), calculated over all patients"},{"cancer_study_identifier":"brca_dldccc_2022","cs.name":"Triple Negative Breast Cancer (DLDCCC, Cancer Discov 2022)","profile_name":"mRNA expression (RNA Seq RSEM)","profile_description":"mRNA gene expression (RNA Seq RSEM)"},{"cancer_study_identifier":"brca_dldccc_2022","cs.name":"Triple Negative Breast Cancer (DLDCCC, Cancer Discov 2022)","profile_name":"mRNA expression z-scores","profile_description":"Expression levels z-scores"}]}
```


I can see that most studies mention "RNA Seq" but don't specify the library preparation method. Let me search more specifically for studies that might have documented their methods differently:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT \n    cs.cancer_study_identifier,\n    cs.name,\n    cs.description\nFROM cancer_study cs\nWHERE cs.description LIKE '%RNA%'\n  AND (cs.description LIKE '%method%' \n    OR cs.description LIKE '%protocol%'\n    OR cs.description LIKE '%library%'\n    OR cs.description LIKE '%preparation%')\nORDER BY cs.cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[]}
```


Let me check if there are any studies with lncRNA data specifically:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT\n    cs.cancer_study_identifier,\n    cs.name,\n    gp.name as profile_name,\n    gp.description as profile_description,\n    gp.genetic_alteration_type\nFROM genetic_profile gp\nJOIN cancer_study cs ON gp.cancer_study_id = cs.cancer_study_id\nWHERE lower(gp.name) LIKE '%lncrna%'\n   OR lower(gp.name) LIKE '%long non%'\n   OR lower(gp.name) LIKE '%noncoding%'\n   OR lower(gp.description) LIKE '%lncrna%'\n   OR lower(gp.description) LIKE '%long non%'\n   OR lower(gp.description) LIKE '%noncoding%'\nORDER BY cs.cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[]}
```


Let me check the available study guides to see if any contain information about RNA-seq methods:



Calling `list_study_guides` with args:
```json
{}
```



Result from `list_study_guides`:
```json
["luad_tcga_pan_can_atlas_2018","coadread_tcga_pan_can_atlas_2018","ucec_tcga_pan_can_atlas_2018","brca_tcga_pan_can_atlas_2018","msk_chord_2024","os_target_gdc","gbm_tcga_pan_can_atlas_2018","ov_tcga_pan_can_atlas_2018"]
```


Let me check a few TCGA studies to see if they have information about RNA-seq methods:



Calling `get_study_guide` with args:
```json
{
  "study_id": "brca_tcga_pan_can_atlas_2018"
}
```



Result from `get_study_guide`:
```json
# Breast Invasive Carcinoma (TCGA, PanCancer Atlas)

**Study ID:** `brca_tcga_pan_can_atlas_2018`

See `_tcga_pancan_template.md` for common TCGA clinical attributes.

## Study-Specific Attributes

### Molecular Subtypes
| Attribute | Description | Values |
|-----------|-------------|--------|
| `SUBTYPE` | PAM50 molecular subtype | Luminal A, Luminal B, HER2-enriched, Basal-like, Normal-like |

### Receptor Status
| Attribute | Description | Notes |
|-----------|-------------|-------|
| `ER_STATUS` | Estrogen receptor status | Positive, Negative |
| `PR_STATUS` | Progesterone receptor status | Positive, Negative |
| `HER2_STATUS` | HER2 receptor status | Positive, Negative, Equivocal |
| `TRIPLE_NEGATIVE` | Triple negative status | Derived from ER/PR/HER2 |

### Histology
| Attribute | Description |
|-----------|-------------|
| `HISTOLOGICAL_TYPE` | Ductal, Lobular, Mixed, etc. |

## Key Genes
- **TP53**: Most frequently mutated (~30%)
- **PIK3CA**: Common in ER+ tumors (~35%)
- **CDH1**: Enriched in lobular carcinoma
- **GATA3**: Luminal marker
- **ERBB2**: HER2 amplification target

## Notes
- Molecular subtypes (PAM50) correlate strongly with clinical behavior
- ER/PR/HER2 status drives treatment decisions
- Lobular vs ductal distinction has different mutation profiles

```


Let me check if there's information in the MCP resources about RNA-seq methods:



Calling `list_mcp_resources` with args:
```json
{}
```



Result from `list_mcp_resources`:
```json
[{"uri":"cbioportal://mutation-frequency-guide","description":"Comprehensive guide for calculating gene mutation frequencies with gene-specific profiling denominators"},{"uri":"cbioportal://clinical-data-guide","description":"Guide for querying clinical data including patient vs sample level considerations"},{"uri":"cbioportal://sample-filtering-guide","description":"Guide for filtering samples and studies in cBioPortal queries"},{"uri":"cbioportal://common-pitfalls","description":"Guide to avoid common mistakes when querying cBioPortal data"},{"uri":"cbioportal://treatment-guide","description":"Guide for querying treatment/clinical event data including drug agents, timelines, and linking to genomic data"},{"uri":"cbioportal://study-guide/{study_id}","description":"Dynamic study-specific guide - use get_study_guide(study_id) tool to generate"}]
```


Let me search for studies that might have documented their sequencing methods in the study description or name:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT \n    cancer_study_identifier,\n    name,\n    description\nFROM cancer_study\nWHERE lower(name) LIKE '%total rna%'\n   OR lower(name) LIKE '%rrna%'\n   OR lower(name) LIKE '%lncrna%'\n   OR lower(name) LIKE '%long non%'\nORDER BY cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[]}
```


Let me check if there are any generic assay profiles that might contain lncRNA data:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT DISTINCT\n    cs.cancer_study_identifier,\n    cs.name,\n    gp.name as profile_name,\n    gp.description as profile_description,\n    gp.generic_assay_type\nFROM genetic_profile gp\nJOIN cancer_study cs ON gp.cancer_study_id = cs.cancer_study_id\nWHERE gp.genetic_alteration_type = 'GENERIC_ASSAY'\n  AND (lower(gp.name) LIKE '%rna%'\n    OR lower(gp.name) LIKE '%lnc%'\n    OR lower(gp.description) LIKE '%rna%'\n    OR lower(gp.description) LIKE '%lnc%')\nORDER BY cs.cancer_study_identifier\nLIMIT 50\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[{"cancer_study_identifier":"gbm_cptac_2021","cs.name":"Glioblastoma (CPTAC, Cell 2021)","profile_name":"cRNA expression (FPKM-UQ)","profile_description":"Expression of circular RNA abundance in FPKM-UQ values","generic_assay_type":"cRNA"},{"cancer_study_identifier":"lusc_cptac_2021","cs.name":"Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)","profile_name":"circular RNA expression (RSEM)","profile_description":"Circular RNA expression by cRNA abundance in RSEM values","generic_assay_type":"cRNA"},{"cancer_study_identifier":"paad_cptac_2021","cs.name":"Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)","profile_name":"cRNA expression (RSEM-UQ)","profile_description":"Expression of circular RNA abundance in RSEM-UQ values","generic_assay_type":"cRNA"},{"cancer_study_identifier":"pog570_bcgsc_2020","cs.name":"Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)","profile_name":"Immune Cell Expression Signatures (Absolute Scores)","profile_description":"Immune Cell Expression Signatures (absolute scores for each cell type) generated by CIBERSORT from RNA-seq RPKM data.","generic_assay_type":"IMMUNE_CELL_SIGNATURE"},{"cancer_study_identifier":"ucec_cptac_2020","cs.name":"Endometrial Carcinoma (CPTAC, Cell 2020)","profile_name":"circular RNA expression (RSEM)","profile_description":"Circular RNA expression by ciRNA abundance in RSEM values.","generic_assay_type":"circular_rna"}]}
```


Interesting! I found circular RNA data. Now let me look more broadly at what studies exist and check if any documentation mentions the library preparation methods. Let me also check if there are studies that explicitly mention they used methods suitable for lncRNA detection:



Calling `clickhouse_run_select_query` with args:
```json
{
  "query": "\nSELECT \n    cancer_study_identifier,\n    name,\n    COUNT(*) as num_profiles\nFROM cancer_study cs\nJOIN genetic_profile gp ON cs.cancer_study_id = gp.cancer_study_id\nWHERE gp.genetic_alteration_type = 'MRNA_EXPRESSION'\nGROUP BY cancer_study_identifier, name\nHAVING num_profiles > 0\nORDER BY cancer_study_identifier\nLIMIT 100\n"
}
```



Result from `clickhouse_run_select_query`:
```json
{"rows":[{"cancer_study_identifier":"acc_tcga","name":"Adrenocortical Carcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"acc_tcga_gdc","name":"Adrenocortical Carcinoma (TCGA GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"acc_tcga_pan_can_atlas_2018","name":"Adrenocortical Carcinoma (TCGA, PanCancer Atlas)","num_profiles":3},{"cancer_study_identifier":"alal_target_gdc","name":"Acute Leukemias of Ambiguous Lineage (TARGET GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"all_phase2_target_2018_pub","name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","num_profiles":7},{"cancer_study_identifier":"aml_ohsu_2018","name":"Acute Myeloid Leukemia (OHSU, Nature 2018)","num_profiles":4},{"cancer_study_identifier":"aml_ohsu_2022","name":"Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)","num_profiles":2},{"cancer_study_identifier":"aml_target_2018_pub","name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","num_profiles":5},{"cancer_study_identifier":"aml_target_gdc","name":"Acute Myeloid Leukemia (TARGET GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"aml_tcga_gdc","name":"Acute Myeloid Leukemia (TCGA GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"angs_painter_2025","name":"The Angiosarcoma Project - Count Me In (Provisional, April 2025)","num_profiles":3},{"cancer_study_identifier":"asclc_msk_2024","name":"Atypical Small Cell Lung Cancer (MSK, Cancer Discov 2024)","num_profiles":2},{"cancer_study_identifier":"blca_bcan_hcrn_2022","name":"Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)","num_profiles":1},{"cancer_study_identifier":"blca_msk_tcga_2020","name":"Bladder Cancer (MSK/TCGA, 2020)","num_profiles":3},{"cancer_study_identifier":"blca_mskcc_solit_2012","name":"Bladder Cancer (MSK, J Clin Onco 2013)","num_profiles":3},{"cancer_study_identifier":"blca_pdx_msk_2025","name":"Urothelial Cancer Patient Derived Organoids (MSK, 2025)","num_profiles":2},{"cancer_study_identifier":"blca_tcga","name":"Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"blca_tcga_gdc","name":"Bladder Urothelial Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"blca_tcga_pan_can_atlas_2018","name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"blca_tcga_pub","name":"Bladder Urothelial Carcinoma (TCGA, Nature 2014)","num_profiles":3},{"cancer_study_identifier":"blca_tcga_pub_2017","name":"Bladder Cancer (TCGA, Cell 2017)","num_profiles":3},{"cancer_study_identifier":"bll_target_gdc","name":"B-Lymphoblastic Leukemia/Lymphoma (TARGET GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"brain_cptac_2020","name":"Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)","num_profiles":2},{"cancer_study_identifier":"brain_cptac_gdc","name":"CNS/Brain Cancer (CPTAC GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"brca_aurora_2023","name":"Metastatic Breast Cancer (AURORA US Network, Nat Cancer 2023)","num_profiles":1},{"cancer_study_identifier":"brca_cptac_2020","name":"Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)","num_profiles":2},{"cancer_study_identifier":"brca_dldccc_2022","name":"Triple Negative Breast Cancer (DLDCCC, Cancer Discov 2022)","num_profiles":2},{"cancer_study_identifier":"brca_mbcproject_2022","name":"The Metastatic Breast Cancer Project (Provisional, December 2021)","num_profiles":2},{"cancer_study_identifier":"brca_mbcproject_wagle_2017","name":"The Metastatic Breast Cancer Project (Archived, 2020)","num_profiles":2},{"cancer_study_identifier":"brca_metabric","name":"Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)","num_profiles":2},{"cancer_study_identifier":"brca_smc_2018","name":"Breast Cancer (SMC 2018)","num_profiles":2},{"cancer_study_identifier":"brca_tcga","name":"Breast Invasive Carcinoma (TCGA, Firehose Legacy)","num_profiles":6},{"cancer_study_identifier":"brca_tcga_gdc","name":"Invasive Breast Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"brca_tcga_pan_can_atlas_2018","name":"Breast Invasive Carcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"brca_tcga_pub","name":"Breast Invasive Carcinoma (TCGA, Nature 2012)","num_profiles":6},{"cancer_study_identifier":"brca_tcga_pub2015","name":"Breast Invasive Carcinoma (TCGA, Cell 2015)","num_profiles":6},{"cancer_study_identifier":"breast_cptac_gdc","name":"Breast Cancer (CPTAC GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"ccle_broad_2019","name":"Cancer Cell Line Encyclopedia (Broad, 2019)","num_profiles":3},{"cancer_study_identifier":"ccle_genentech_2014","name":"Cancer Cell Line Encyclopedia (Genentech, Nat biotech 2014)","num_profiles":2},{"cancer_study_identifier":"ccrcc_tcga_gdc","name":"Renal Clear Cell Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"cellline_ccle_broad","name":"Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 2012)","num_profiles":3},{"cancer_study_identifier":"cellline_nci60","name":"NCI-60 Cell Lines (NCI, Cancer Res 2012)","num_profiles":1},{"cancer_study_identifier":"cesc_tcga","name":"Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"cesc_tcga_gdc","name":"Cervical Squamous Cell Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"cesc_tcga_pan_can_atlas_2018","name":"Cervical Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","num_profiles":3},{"cancer_study_identifier":"chol_tcga","name":"Cholangiocarcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"chol_tcga_gdc","name":"Cholangiocarcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"chol_tcga_pan_can_atlas_2018","name":"Cholangiocarcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"chrcc_tcga_gdc","name":"Chromophobe Renal Cell Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"cll_broad_2015","name":"Chronic Lymphocytic Leukemia (Broad, Nature 2015)","num_profiles":2},{"cancer_study_identifier":"cll_broad_2022","name":"Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)","num_profiles":2},{"cancer_study_identifier":"coad_cptac_2019","name":"Colon Cancer (CPTAC-2 Prospective, Cell 2019)","num_profiles":3},{"cancer_study_identifier":"coad_cptac_gdc","name":"Colon Adenocarcinoma (CPTAC GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"coad_silu_2022","name":"Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)","num_profiles":2},{"cancer_study_identifier":"coad_tcga_gdc","name":"Colon Adenocarcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"coadread_tcga","name":"Colorectal Adenocarcinoma (TCGA, Firehose Legacy)","num_profiles":6},{"cancer_study_identifier":"coadread_tcga_pan_can_atlas_2018","name":"Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"coadread_tcga_pub","name":"Colorectal Adenocarcinoma (TCGA, Nature 2012)","num_profiles":9},{"cancer_study_identifier":"crc_hta11_htan_2021","name":"Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)","num_profiles":2},{"cancer_study_identifier":"difg_glass","name":"Diffuse Glioma (GLASS Consortium)","num_profiles":2},{"cancer_study_identifier":"difg_glass_2019","name":"Diffuse Glioma (GLASS Consortium, Nature 2019)","num_profiles":2},{"cancer_study_identifier":"difg_tcga_gdc","name":"Diffuse Glioma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"dlbc_tcga","name":"Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"dlbc_tcga_pan_can_atlas_2018","name":"Diffuse Large B-Cell Lymphoma (TCGA, PanCancer Atlas)","num_profiles":3},{"cancer_study_identifier":"dlbclnos_tcga_gdc","name":"Diffuse Large B-Cell Lymphoma, NOS (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"esca_tcga","name":"Esophageal Carcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"esca_tcga_gdc","name":"Esophageal Adenocarcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"esca_tcga_pan_can_atlas_2018","name":"Esophageal Adenocarcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"gbm_cptac_2021","name":"Glioblastoma (CPTAC, Cell 2021)","num_profiles":5},{"cancer_study_identifier":"gbm_mayo_pdx_sarkaria_2019","name":"Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)","num_profiles":3},{"cancer_study_identifier":"gbm_tcga","name":"Glioblastoma Multiforme (TCGA, Firehose Legacy)","num_profiles":9},{"cancer_study_identifier":"gbm_tcga_gdc","name":"Glioblastoma Multiforme (TCGA GDC, 2025)","num_profiles":6},{"cancer_study_identifier":"gbm_tcga_pan_can_atlas_2018","name":"Glioblastoma Multiforme (TCGA, PanCancer Atlas)","num_profiles":3},{"cancer_study_identifier":"gbm_tcga_pub","name":"Glioblastoma (TCGA, Nature 2008)","num_profiles":6},{"cancer_study_identifier":"gbm_tcga_pub2013","name":"Glioblastoma (TCGA, Cell 2013)","num_profiles":3},{"cancer_study_identifier":"hcc_clca_2024","name":"Hepatocellular Carcinoma (CLCA, Nature 2024)","num_profiles":2},{"cancer_study_identifier":"hcc_tcga_gdc","name":"Hepatocellular Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"hgsoc_tcga_gdc","name":"High-Grade Serous Ovarian Cancer (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"hnsc_a5consortium_2025","name":"Hereditary SDHB-Mutant Pheochromocytomas and Paragangliomas (A5 Consortium, Nature Comm 2025)","num_profiles":2},{"cancer_study_identifier":"hnsc_tcga","name":"Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"hnsc_tcga_gdc","name":"Head and Neck Squamous Cell Carcinoma (TCGA, GDC)","num_profiles":6},{"cancer_study_identifier":"hnsc_tcga_pan_can_atlas_2018","name":"Head and Neck Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"hnsc_tcga_pub","name":"Head and Neck Squamous Cell Carcinoma (TCGA, Nature 2015)","num_profiles":3},{"cancer_study_identifier":"kich_tcga","name":"Kidney Chromophobe (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"kich_tcga_pan_can_atlas_2018","name":"Kidney Chromophobe (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"kich_tcga_pub","name":"Kidney Chromophobe (TCGA, Cancer Cell 2014)","num_profiles":3},{"cancer_study_identifier":"kirc_tcga","name":"Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)","num_profiles":6},{"cancer_study_identifier":"kirc_tcga_pan_can_atlas_2018","name":"Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"kirc_tcga_pub","name":"Kidney Renal Clear Cell Carcinoma (TCGA, Nature 2013)","num_profiles":9},{"cancer_study_identifier":"kirp_tcga","name":"Kidney Renal Papillary Cell Carcinoma (TCGA, Firehose Legacy)","num_profiles":6},{"cancer_study_identifier":"kirp_tcga_pan_can_atlas_2018","name":"Kidney Renal Papillary Cell Carcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"laml_tcga","name":"Acute Myeloid Leukemia (TCGA, Firehose Legacy)","num_profiles":6},{"cancer_study_identifier":"laml_tcga_pan_can_atlas_2018","name":"Acute Myeloid Leukemia (TCGA, PanCancer Atlas)","num_profiles":3},{"cancer_study_identifier":"laml_tcga_pub","name":"Acute Myeloid Leukemia (TCGA, NEJM 2013)","num_profiles":3},{"cancer_study_identifier":"lgg_tcga","name":"Brain Lower Grade Glioma (TCGA, Firehose Legacy)","num_profiles":6},{"cancer_study_identifier":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","num_profiles":3},{"cancer_study_identifier":"lihc_tcga","name":"Liver Hepatocellular Carcinoma (TCGA, Firehose Legacy)","num_profiles":3},{"cancer_study_identifier":"lihc_tcga_pan_can_atlas_2018","name":"Liver Hepatocellular Carcinoma (TCGA, PanCancer Atlas)","num_profiles":4},{"cancer_study_identifier":"luad_cas_2020","name":"Lung Adenocarcinoma (CAS, Cell 2020)","num_profiles":2},{"cancer_study_identifier":"luad_cptac_2020","name":"Lung Adenocarcinoma (CPTAC, Cell 2020)","num_profiles":4}]}
```


Based on my investigation of the cBioPortal database, I need to provide you with an important finding:

## Answer

**Unfortunately, the cBioPortal database does not systematically document RNA library preparation methods** (such as polyA enrichment vs. rRNA depletion) in the study metadata or genetic profile descriptions. 

Here's what I found:

### Limited Documentation
1. **Only one study explicitly mentions polyA**: The **Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)** study (`prad_su2c_2019`) has profiles specifically labeled as "mRNA expression (FPKM polyA)" and "mRNA expression z-scores (FPKM polyA)", indicating polyA enrichment was used.

2. **No studies explicitly mention rRNA depletion or total RNA** in their profile descriptions within the database.

3. **No lncRNA-specific profiles** were found in the database, though some studies do have circular RNA (cRNA) data.

### Why This Matters for lncRNA Research
- **PolyA enrichment** captures primarily polyadenylated transcripts (most mRNAs) but misses many lncRNAs that lack polyA tails
- **rRNA depletion/total RNA** methods are better for capturing the full transcriptome including non-polyadenylated lncRNAs

### Recommendations
To find studies suitable for lncRNA research, you would need to:

1. **Check the original publications** associated with each study - the methods sections would describe library preparation
2. **Focus on TCGA studies** - TCGA typically used polyA enrichment, so they may not be ideal for comprehensive lncRNA analysis
3. **Look for more recent studies** (2020+) which are more likely to use rRNA depletion methods
4. **Contact study authors** directly to confirm library preparation methods

Would you like me to help you find contact information or publication details for specific studies that might be suitable for lncRNA research?

---

## Model Information
- **model**: us.anthropic.claude-sonnet-4-5-20250929-v1:0
- **temperature**: 0.0
- **max_output_tokens**: 1024
- **thinking_enabled**: False
- **thinking_budget_tokens**: 1024
- **response_time_seconds**: 74.76061084098183
- **agent_type**: mcp-clickhouse

### Usage
- **input_tokens**: 260900
- **output_tokens**: 3693
- **total_tokens**: 264593
- **cache_creation_input_tokens**: 0
- **cache_read_input_tokens**: 0

---

*Generated on 2026-02-05 13:28:24*